Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mycophenolate Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 232Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aurobindo Pharma`s Generic Mycophenolic Sodium Receives Approval in the U.S.
    Aurobindo Pharma`s Generic Mycophenolic Sodium Receives Approval in the U.S.

    27 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218603

    FDA
    27 Feb 2024
    Share Share
    Mylan Lab Inc initiates Class II recall of Mycophenolic Acid due to failed dissolution specifications
    Mylan Lab Inc initiates Class II recall of Mycophenolic Acid due to failed dissolution specifications

    11 Jun 2015

    // FDA

    http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-1111-2015&w=06102015&lang=eng

    FDA
    11 Jun 2015
    Share Share
    CellCept,MYFORTIC-Risk of Teratogenicity in Mycophenolate-Containing Products
    CellCept,MYFORTIC-Risk of Teratogenicity in Mycophenolate-Containing Products

    12 Jan 2015

    // HEALTH CANADA

    http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/56690a-eng.php

    HEALTH CANADA
    12 Jan 2015
    Share Share